Nausea And Vomiting Therapeutics
1. Aloxi patent expiration
Treatment: Prevention of postoperative nausea and vomiting; Prevention of chemotherapy-induced nau...
ALOXI's oppositions filed in EPO
ALOXI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9125905 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US8598219 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
|
US8598219 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
| US5202333 | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Apr, 2015
(10 years ago) | |
|
US5202333 (Pediatric) | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Oct, 2015
(10 years ago) | |
| US9066980 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US8729094 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US9457021 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US7947725 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US7960424 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US8518981 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US9439854 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US8598218 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US9173942 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US9457020 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US7947724 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
|
US7947724 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US7947725 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US7960424 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US8729094 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US8518981 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US8598218 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9173942 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9125905 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9439854 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9457020 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9457021 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9066980 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 22, 2011 |
| New Indication(I-684) | May 27, 2017 |
| M(M-136) | May 27, 2017 |
| Pediatric Exclusivity(PED) | Nov 27, 2017 |
Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 29 February, 2008
Dosage: INJECTABLE; CAPSULE
How can I launch a generic of ALOXI before it's drug patent expiration?
More Information on Dosage
ALOXI family patents
2. Emend patent expiration
Treatment: Treatment or prevention of emesis; Prevention of postoperative nausea and vomiting
EMEND's oppositions filed in EPO
EMEND IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214692 | MSD | Medical use for tachykinin antagonists |
Sep, 2012
(13 years ago) | |
| US5538982 | MSD | Medical use for tachykinin antagonists |
Jul, 2013
(12 years ago) | |
| US5719147 | MSD | Morpholine and thiomorpholine tachykinin receptor antagonists |
Apr, 2015
(10 years ago) | |
| US6096742 | MSD | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(7 years ago) | |
| US8258132 | MSD | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 30 June, 2006
Dosage: CAPSULE
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
3. Emend patent
expiration
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
EMEND's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6096742 | MSD MERCK CO | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Dosage: FOR SUSPENSION
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
4. Emend patent expiration
Treatment: Prevention or treatment of nausea or emesis induced by a cancer chemotherapeutic agent
EMEND IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5512570 | MERCK AND CO INC | Treatment of emesis with morpholine tachykinin receptor antagonists |
Mar, 2014
(11 years ago) | |
| US5538982 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Jul, 2013
(12 years ago) | |
| US7214692 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Sep, 2012
(13 years ago) | |
| US5716942 | MERCK AND CO INC | Treatment of migraine with morpholine tachykinin receptor antagonists |
Feb, 2015
(10 years ago) | |
| US5691336 | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Mar, 2019
(6 years ago) | |
|
US5691336 (Pediatric) | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Sep, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient
NCE-1 date: 03 October, 2020
Market Authorisation Date: 25 January, 2008
Dosage: POWDER
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
5. Varubi patent expiration
Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy
VARUBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7049230 | TERSERA | Method of forming a contact plug in a semiconductor device |
Dec, 2023
(2 years ago) | |
| US7049320 | TERSERA | NK1 antagonists |
Aug, 2028
(2 years from now) | |
| US8178550 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Apr, 2027
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796299 | TERSERA | NK1 antagonists |
Dec, 2022
(3 years ago) | |
| US7981905 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(1 year, 2 months from now) | |
| US8470842 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Jan, 2029
(3 years from now) | |
| US8404702 | TERSERA | Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(1 year, 2 months from now) | |
| US9101615 | TERSERA | Intravenous formulations of neurokinin-1 antagonists |
Jul, 2032
(6 years from now) | |
| US7563801 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(1 year, 2 months from now) | |
| US8361500 | TERSERA | Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom |
Oct, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 01, 2020 |
Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient
NCE-1 date: 02 September, 2019
Market Authorisation Date: 25 October, 2017
Dosage: EMULSION; TABLET
More Information on Dosage
VARUBI family patents